This Pot Stock’s Sales Doubled in Q2 — and It’s Raising Its Guidance

Harvest Health & Recreation (CNSX:HARV) is coming off a strong quarter that featured improvements in both its top and bottom lines.

| More on:
woman data analyze

Image source: Getty Images.

One industry that continues to do well amid the COVID-19 pandemic is cannabis. Sales are up in Canada and south of the border and many states are seeing record numbers. People are stocking up on pot, whether it’s for medicinal reasons or just because they’re bored and staying at home, and that’s translating into some great performances by many marijuana companies.

One company that’s coming off a great quarter is Arizona-based Harvest Health & Recreation (CNSX:HARV). The vertically integrated marijuana company released its second-quarter results for the period ending June 30 and sales totaling US$55.7 million grew by 109% year over year and 26% from the previous quarter.

More positives from the company’s financials

Sales growth alone isn’t all that exciting, especially from U.S.-based cannabis companies where many of them are still in their early growth stages. But what’s perhaps even more important is that Harvest Health’s adjusted EBITDA of US$4.1 million was positive and a big improvement from the US$3.6 million loss that it incurred in the first quarter. Its total net loss of US$18.3 million was also a slight improvement from its Q1 loss of US$20 million.

Another encouraging figure was that the company’s gross margin, excluding biological adjustments, came in at just over 42%, slightly higher than the 41% margin it achieved in Q1. With stability in its margins and financials, Harvest Health has an advantage over many other cannabis companies that are still deep in the red and showing little (if any progress).

What’s more is that with more revenue growth, Harvest Health’s financials can continue to get stronger, especially if its margins remain intact. And the company’s optimistic about the rest of the year. In its earnings release, Harvest Health announced it was raising its revenue guidance from US$200 million for 2020 up to a range between US$215 million to US$220 million.

At the top end of that range, that would represent a year-over-year sales growth of 88% from the US$117 million in sales that Harvest Health generated in 2019.

The company’s financial position is also improving, with cash and cash equivalents of US$61.7 million on June 30 rising from the US$22.7 million that Harvest Health reported at the end of 2019. With a good cash position, growing sales and positive EBITDA, Harvest Health ticks off many of the checkmarks that cannabis investors are looking for in a good pot stock today.

Is Harvest Health a buy?

Year to date, Harvest Health’s underperformed the Horizons Marijuana Life Sciences Index ETF (HMMJ.TO):

HARV Chart

HARV data by YCharts

However, with a depressed stock price, now could be an advantageous time for investors to invest in Harvest Health. As you can see, it compares favourably against many of its peers and top pot stocks:

HARV PS Ratio Chart

HARV PS Ratio data by YCharts

Investors who buy shares of Harvest Health aren’t paying much of a premium for it today. And with a low price-to-sales to go along with some strong financial numbers, it may be one of the better cannabis investments out there today, especially with the industry doing so well in the U.S. amid the COVID-19 pandemic and showing no signs of slowing down just yet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. 

More on Investing


Got $5,000? Buy and Hold These 3 Value Stocks for Years

Given their solid underlying businesses, healthy growth prospects, and attractive valuation, I am bullish on these three value stocks.

Read more »

money cash dividends
Stocks for Beginners

Got $1,000 to Invest in Stocks? Put It in This Index Fund

This low-cost beginner-friendly ETF is a great way to invest $1,000.

Read more »

Overhead shot of young adults using technology at a table
Tech Stocks

3 Cheap Tech Stocks to Buy Right Now

Given their long-term growth prospects and discounted stock prices, I am bullish on these tech stocks.

Read more »

money cash dividends
Dividend Stocks

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

Want some absurdly cheap stocks for your portfolio? Here are two options trading at a huge discount right now.

Read more »

Gas pipelines
Dividend Stocks

TFSA Passive Income: Is Enbridge Stock a Buy, Sell, or Hold?

Enbridge now offers a yield near 8%. Is the dividend safe?

Read more »

A worker uses the cloud for paperless work. tech
Tech Stocks

Wanna Beat the Market? Try These 2 Tech Stocks That Look Undervalued Today

Here's why undervalued TSX stocks such as Vitalhub can help you generate outsized gains in the next 12 months.

Read more »

Redwood trees stretch up to the sunlight.
Tech Stocks

These 3 Magnificent Stocks Keep Driving Higher

Constellation Software, Dollarama and another TSX stock have consistently generated positive investment returns. Here’s why they belong in your retirement…

Read more »

sale discount best price
Dividend Stocks

3 Stocks to Buy While They Are on Sale

Top TSX dividend stocks are trading at discounted prices.

Read more »